MedTrace Logo

FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

NCT03761173 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-10-01

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE). The use of the device will be assessed in a real-world population, with eligibility criteria that closely approximate its use in clinical practice.

Up to 300 additional patients with anticoagulation treatment as the initial planned primary treatment strategy for intermediate risk PE will also be evaluated (US only).

Conditions

  • PE - Pulmonary Embolism
  • PE - Pulmonary Thromboembolism

Interventions

DEVICE

FlowTriever System

Thrombectomy

DRUG

Anticoagulation Agents

Anticoagulation medication

Sponsors & Collaborators

  • Inari Medical

    lead INDUSTRY

Principal Investigators

  • Catalin Toma, MD · University of Pittsburgh

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-15
Primary Completion
2024-09-04
Completion
2024-09-04

Countries

  • United States
  • Austria
  • Belgium
  • France
  • Germany
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03761173 on ClinicalTrials.gov